TY - JOUR
T1 - Extremity exposure in nuclear medicine therapy with 90Y-labelled substances – Results of the ORAMED project
AU - Rimpler, A.
AU - Barth, I.
AU - Ferrari, Paolo
AU - Baechler, Sebastien
AU - Carnicer, Adela
AU - Donadille, Laurent
AU - Fulop, M.
AU - Ginjaume, Mercè
AU - Mariotti, M.
AU - Sans-Mercé, Marta
AU - Gualdrini, G.
AU - Krim, Sabah
AU - Ortega, Xavier
AU - Ruiz, Natasha
AU - Vanhavere, Filip
N1 - Score=10
PY - 2011/11
Y1 - 2011/11
N2 - 90Y-labelled radiopharmaceuticals offer promising prospects for radionuclide therapies of tumours, e.g. radioimmunotherapies (RIT), (EANM, 2007), peptide receptor radiotherapies (PRRT), (Otte et al., 1998), and selective internal radiotherapies (SIRT), (Salem and Thurston, 2006). 90Y, an almost pure high-energy beta radiation emitter (Eβ,max = 2.28 MeV), is a favourable radionuclide for therapeutic purposes. However, when preparing and performing these therapies, high activities of 90Y (>1 GBq) are to be manipulated and technicians, physicians and nurses may receive high skin exposures to the hands. If radiation protection standards are low, the exposure of staff can exceed the annual skin dose limit of 500 mSv. Within a particular work package (WP4) of the ORAMED project, comprehensive measurements in nuclear medicine departments of several hospitals in 6 European countries were carried out. The study focussed on 90Y-labelled substances such as Zevalin® and DOTATOC to achieve a representative database on staff exposure. This paper summarises the most important results and conclusions for individual monitoring of skin exposure of staff.
AB - 90Y-labelled radiopharmaceuticals offer promising prospects for radionuclide therapies of tumours, e.g. radioimmunotherapies (RIT), (EANM, 2007), peptide receptor radiotherapies (PRRT), (Otte et al., 1998), and selective internal radiotherapies (SIRT), (Salem and Thurston, 2006). 90Y, an almost pure high-energy beta radiation emitter (Eβ,max = 2.28 MeV), is a favourable radionuclide for therapeutic purposes. However, when preparing and performing these therapies, high activities of 90Y (>1 GBq) are to be manipulated and technicians, physicians and nurses may receive high skin exposures to the hands. If radiation protection standards are low, the exposure of staff can exceed the annual skin dose limit of 500 mSv. Within a particular work package (WP4) of the ORAMED project, comprehensive measurements in nuclear medicine departments of several hospitals in 6 European countries were carried out. The study focussed on 90Y-labelled substances such as Zevalin® and DOTATOC to achieve a representative database on staff exposure. This paper summarises the most important results and conclusions for individual monitoring of skin exposure of staff.
KW - Nuclear medicine
KW - Radiation exposure
KW - Skin dose
KW - Individual monitoring
UR - https://ecm.sckcen.be/OTCS/llisapi.dll/overview/ezp_124593
U2 - 10.1016/j.radmeas.2011.05.068
DO - 10.1016/j.radmeas.2011.05.068
M3 - Article
SN - 1350-4487
VL - 46
SP - 1283
EP - 1286
JO - Radiation Measurements
JF - Radiation Measurements
IS - 11
ER -